Employing Feature Selection Algorithms to Determine the Immune State of a Mouse Model of Rheumatoid Arthritis

• URL: http://arxiv.org/abs/2207.05882v2
• Date: Sat, 21 Oct 2023 19:55:54 GMT
• Title: Employing Feature Selection Algorithms to Determine the Immune State of a Mouse Model of Rheumatoid Arthritis
• Authors: Brendon K. Colbert, Joslyn L. Mangal, Aleksandr Talitckii, Abhinav P. Acharya and Matthew M. Peet
• Abstract summary: The immune response is a dynamic process by which the body determines whether an antigen is self or nonself. The goal of immunotherapy as applied to, e.g. Rheumatoid Arthritis (RA), is to bias the immune state in favor of the regulatory actors.
• Score: 43.410962336636224
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: The immune response is a dynamic process by which the body determines whether an antigen is self or nonself. The state of this dynamic process is defined by the relative balance and population of inflammatory and regulatory actors which comprise this decision making process. The goal of immunotherapy as applied to, e.g. Rheumatoid Arthritis (RA), then, is to bias the immune state in favor of the regulatory actors - thereby shutting down autoimmune pathways in the response. While there are several known approaches to immunotherapy, the effectiveness of the therapy will depend on how this intervention alters the evolution of this state. Unfortunately, this process is determined not only by the dynamics of the process, but the state of the system at the time of intervention - a state which is difficult if not impossible to determine prior to application of the therapy. To identify such states we consider a mouse model of RA (Collagen-Induced Arthritis (CIA)) immunotherapy; collect high dimensional data on T cell markers and populations of mice after treatment with a recently developed immunotherapy for CIA; and use feature selection algorithms in order to select a lower dimensional subset of this data which can be used to predict both the full set of T cell markers and populations, along with the efficacy of immunotherapy treatment.

Related papers

• Generative Humanization for Therapeutic Antibodies [4.456125565993172]
  Humanization is a sequence optimization strategy that addresses one critical risk called immunogenicity. We re-frame humanization as a conditional generative modeling task, where humanizing mutations are sampled from a language model trained on human antibody data. We describe a sampling process that incorporates models of therapeutic attributes, such as antigen binding affinity, to obtain candidate sequences that have both reduced immunogenicity risk and maintained or improved therapeutic properties.
  arXiv  Detail & Related papers  (2024-12-06T02:54:45Z)
• Harnessing Preference Optimisation in Protein LMs for Hit Maturation in Cell Therapy [0.5315454965484603]
  Cell and immunotherapy offer transformative potential for treating diseases like cancer and autoimmune disorders by modulating the immune system. The development of these therapies is resource-intensive, with the majority of drug candidates failing to progress beyond laboratory testing. Recent advances in machine learning have revolutionised areas such as protein engineering, applications in immunotherapy remain limited due to the scarcity of large-scale, standardised datasets and the complexity of cellular systems.
  arXiv  Detail & Related papers  (2024-12-02T11:21:58Z)
• Quantifying Aleatoric Uncertainty of the Treatment Effect: A Novel Orthogonal Learner [72.20769640318969]
  Estimating causal quantities from observational data is crucial for understanding the safety and effectiveness of medical treatments. Medical practitioners require not only estimating averaged causal quantities, but also understanding the randomness of the treatment effect as a random variable. This randomness is referred to as aleatoric uncertainty and is necessary for understanding the probability of benefit from treatment or quantiles of the treatment effect.
  arXiv  Detail & Related papers  (2024-11-05T18:14:49Z)
• A unified cross-attention model for predicting antigen binding specificity to both HLA and TCR molecules [4.501817929699959]
  The immune checkpoint inhibitors have demonstrated promising clinical efficacy across various tumor types. The bindings between tumor antigens and HLA-I/TCR molecules determine the antigen presentation and T-cell activation. We propose UnifyImmun, a unified cross-attention transformer model designed to simultaneously predict the bindings of peptides to both receptors.
  arXiv  Detail & Related papers  (2024-04-08T08:25:25Z)
• AI driven B-cell Immunotherapy Design [0.0]
  The effectiveness of antigen neutralisation and elimination hinges upon the strength, sensitivity, and specificity of the paratope-epitope interaction. In recent years, artificial intelligence and machine learning methods have made significant strides, revolutionising the prediction of protein structures and their complexes. This review focuses on the progress of machine learning-based tools and their frameworks in the domain of B-cell immunotherapy design.
  arXiv  Detail & Related papers  (2023-09-03T09:14:10Z)
• Non-Linear Self Augmentation Deep Pipeline for Cancer Treatment outcome Prediction [7.455416595124159]
  Authors present an innovative strategy that harnesses a non-linear cellular architecture in conjunction with a deep downstream classifier. This approach aims to carefully select and enhance 2D features extracted from chest-abdomen CT images, thereby improving the prediction of treatment outcomes. The proposed pipeline has been meticulously designed to seamlessly integrate with an advanced embedded Point of Care system.
  arXiv  Detail & Related papers  (2023-07-26T15:01:26Z)
• Dense Feature Memory Augmented Transformers for COVID-19 Vaccination Search Classification [60.49594822215981]
  This paper presents a classification model for detecting COVID-19 vaccination related search queries. We propose a novel approach of considering dense features as memory tokens that the model can attend to. We show that this new modeling approach enables a significant improvement to the Vaccine Search Insights (VSI) task.
  arXiv  Detail & Related papers  (2022-12-16T13:57:41Z)
• Exploiting segmentation labels and representation learning to forecast therapy response of PDAC patients [60.78505216352878]
  We propose a hybrid deep neural network pipeline to predict tumour response to initial chemotherapy. We leverage a combination of representation transfer from segmentation to classification, as well as localisation and representation learning. Our approach yields a remarkably data-efficient method able to predict treatment response with a ROC-AUC of 63.7% using only 477 datasets in total.
  arXiv  Detail & Related papers  (2022-11-08T11:50:31Z)
• MIA-Prognosis: A Deep Learning Framework to Predict Therapy Response [58.0291320452122]
  This paper aims at a unified deep learning approach to predict patient prognosis and therapy response. We formalize the prognosis modeling as a multi-modal asynchronous time series classification task. Our predictive model could further stratify low-risk and high-risk patients in terms of long-term survival.
  arXiv  Detail & Related papers  (2020-10-08T15:30:17Z)
• Estimating Counterfactual Treatment Outcomes over Time Through Adversarially Balanced Representations [114.16762407465427]
  We introduce the Counterfactual Recurrent Network (CRN) to estimate treatment effects over time. CRN uses domain adversarial training to build balancing representations of the patient history. We show how our model achieves lower error in estimating counterfactuals and in choosing the correct treatment and timing of treatment.
  arXiv  Detail & Related papers  (2020-02-10T20:47:36Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.